HLS Therapeutics Inc. (HLS.TO)

4.7500 +0.1000 (+2.15%) At close: 02:06PM EDT

HLS Therapeutics Inc.

10 Carlson Court
Suite 701
Etobicoke, ON M9W 6L2
Canada
647 495 9000
https://www.hlstherapeutics.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 91

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Jason A. Gross Pharm.D.	Vice President of Scientific Affairs	356.38k	N/A	1965
Mr. Ryan C. Lennox B.A., J.D.	Senior VP of Legal, HR & Compliance and Corporate Secretary	391.69k	N/A	1981
Mr. Craig Stuart Millian M.B.A.	CEO & Director	N/A	N/A	1968
Mr. John Hanna CPA, CGA, M.B.A.	Interim CFO & Non-Independent Director	N/A	N/A	N/A
Brian T. Walsh	Senior Vice President of Commercial	N/A	N/A	N/A
Mr. David Spence	VP & Corporate Controller	N/A	N/A	1968

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

Corporate Governance

HLS Therapeutics Inc.’s ISS Governance QualityScore as of May 1, 2024 is 4. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 8; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.